
PACB Stock Forecast & Price Target
PACB Analyst Ratings
Bulls say
Pacific Biosciences of California Inc. is positioned positively due to favorable placement and utilization trends for its Revio sequencing platform, indicating strong customer adoption that supports revenue growth. The company's management has expressed confidence in returning to growth this year, despite the challenges posed by the macroeconomic environment. Additionally, Pacific Biosciences has pursued strategic acquisitions, further strengthening its organic growth profile and suggesting potential for future market expansion.
Bears say
Pacific Biosciences of California Inc faces significant risks that could adversely impact its financial outlook, primarily stemming from stagnant utilization rates and weaker-than-expected demand for new instruments, which may jeopardize 2026 financial targets. Additionally, the company is challenged by demand weakness in China, which is anticipated to continue throughout 2023 and into 2024, potentially resulting in lost market share if competitors introduce superior products. Furthermore, reduced research budgets and tighter funding environments for academic and pharmaceutical institutions may constrain customers' purchasing power, directly affecting Pacific Biosciences' growth prospects.
This aggregate rating is based on analysts' research of Pacific Biosciences of California and is not a guaranteed prediction by Public.com or investment advice.
PACB Analyst Forecast & Price Prediction
Start investing in PACB
Order type
Buy in
Order amount
Est. shares
0 shares